CD4 t cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of vzv infection

PLoS Pathogens

Volumn 7, Issue 11, 2011, Pages

  Haberthur, Kristen ^a   Engelmann, Flora ^a   Park, Byng ^a   Barron, Alex ^a   Legasse, Alfred ^b   Dewane, Jesse ^b   Fischer, Miranda ^b   Kerns, Amelia ^a   Brown, Monica ^a   Messaoudi, Ilhem ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN;

AGAMMAGLOBULINEMIA; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHICKENPOX; CONTROLLED STUDY; DISEASE SEVERITY; INFECTION CONTROL; LYMPHOCYTE PROLIFERATION; MACACA MULATTA; MEMORY CELL; NONHUMAN; VIRUS LOAD; VIRUS REACTIVATION;

ANIMALS; ANTIGENS, CD20; ANTIGENS, CD4; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHICKENPOX; CHICKENPOX VACCINE; DISEASE MODELS, ANIMAL; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 3, HUMAN; MACACA MULATTA; VARICELLOVIRUS; VIRAL LOAD; VIRUS REPLICATION;

ANIMALIA; CERCOPITHECINE HERPESVIRUS 9; HERPES ZOSTER; HUMAN HERPESVIRUS 3; MACACA MULATTA; PRIMATES; SAL VIEJA VIRUS;

EID: 81755187231     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002367     Document Type: Article

References (66)

1. Arvin AM, (2000) Varicella-Zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 6: 219-230.
2. Nagel MA, Cohrs RJ, Mahalingam R, Wellish MC, Forghani B, et al. (2008) The varicella zoster virus vasculopathies: Clinical, CSF, imaging, and virologic features. Neurology 70: 853-860.
3. Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA, (2008) Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. Neurol Clin 26: 675-697, viii.
4. Ragozzino MW, Melton3rd LJ, Kurland LT, Chu CP, Perry HO, (1982) Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 61: 310-316.
5. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA, (2005) The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 20: 748-753.
6. Weaver BA, (2009) Herpes Zoster Overview: Natural History and Incidence. J Am Osteopath Assoc 109: S2-6.
7. Goulleret N, Mauvisseau E, Essevaz-Roulet M, Quinlivan M, Breuer J, (2010) Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP). Vaccine 28: 5878-5882.
8. Marin M, Zhang JX, Seward JF, (2011) Near Elimination of Varicella Deaths in the US After Implementation of the Vaccination Program. Pediatrics 128: 214-220.
9. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, et al. (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352: 2271-2284.
10. Oxman MN, Levin MJ, (2008) Vaccination against Herpes Zoster and Postherpetic Neuralgia. J Infect Dis 197 (Suppl 2): S228-236.
11. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, et al. (2008) Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 197: 825-835.
12. Arvin AM, (1996) Immune responses to varicella-zoster virus. Infect Dis Clin North Am 10: 529-570.
13. Schmader K, (2001) Herpes zoster in older adults. Clin Infect Dis 32: 1481-1486.
14. Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, et al. (1982) Immune responses to varicella-zoster in the aged. Arch Intern Med 142: 291-293.
15. Berger R, Florent G, Just M, (1981) Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun 32: 24-27.
16. Arvin AM, Koropchak CM, Williams BR, Grumet FC, Foung SK, (1986) Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J Infect Dis 154: 422-429.
17. Nader S, Bergen R, Sharp M, Arvin AM, (1995) Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis 171: 13-17.
18. Redman RL, Nader S, Zerboni L, Liu C, Wong RM, et al. (1997) Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 176: 578-585.
19. Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM, (1992) Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 165: 119-126.
20. Zerboni L, Nader S, Aoki K, Arvin AM, (1998) Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J Infect Dis 177: 1701-1704.
21. Arvin AM, Pollard RB, Rasmussen LE, Merigan TC, (1978) Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. J Infect Dis 137: 531-540.
22. Camitta B, Chusid MJ, Starshak RJ, Gottschall JL, (1994) Use of irradiated lymphocytes from immune donors for treatment of disseminated varicella. J Pediatr 124: 593-596.
23. Paryani SG, Arvin AM, Koropchak CM, Dobkin MB, Wittek AE, et al. (1984) Comparison of varicella zoster antibody titers in patients given intravenous immune serum globulin or varicella zoster immune globulin. J Pediatr 105: 200-205.
24. Brunell PA, Ross A, Miller LH, Kuo B, (1969) Prevention of varicella by zoster immune globulin. N Engl J Med 280: 1191-1194.
25. Orenstein WA, Heymann DL, Ellis RJ, Rosenberg RL, Nakano J, et al. (1981) Prophylaxis of varicella in high-risk children: dose-response effect of zoster immune globulin. J Pediatr 98: 368-373.
26. Weigle KA, Grose C, (1984) Molecular dissection of the humoral immune response to individual varicella-zoster viral proteins during chickenpox, quiescence, reinfection, and reactivation. J Infect Dis 149: 741-749.
27. Jura E, Chadwick EG, Josephs SH, Steinberg SP, Yogev R, et al. (1989) Varicella-zoster virus infections in children infected with human immunodeficiency virus. Pediatr Infect Dis J 8: 586-590.
28. Abendroth A, Slobedman B, Lee E, Mellins E, Wallace M, et al. (2000) Modulation of major histocompatibility class II protein expression by varicella-zoster virus. J Virol 74: 1900-1907.
29. Jones L, Black AP, Malavige GN, Ogg GS, (2006) Persistent High Frequencies of Varicella-Zoster Virus ORF4 Protein-Specific CD4+ T Cells after Primary Infection. J Virol 80: 9772-9778.
30. Malavige GN, Jones L, Black AP, Ogg GS, (2007) Rapid Effector Function of Varicella-Zoster Virus Glycoprotein I-Specific CD4 + T Cells Many Decades after Primary Infection. J Infect Dis 195: 660-664.
31. Arvin AM, Sharp M, Smith S, Koropchak CM, Diaz PS, et al. (1991) Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J Immunol 146: 257-264.
32. Frey CR, Sharp MA, Min AS, Schmid DS, Loparev V, et al. (2003) Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination. J Infect Dis 188: 40-52.
33. Asanuma H, Sharp M, Maecker HT, Maino VC, Arvin AM, (2000) Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis 181: 859-866.
34. Abendroth A, Arvin AM, (2001) Immune evasion as a pathogenic mechanism of varicella zoster virus. Semin Immunol 13: 27-39.
35. Kinchington PR, (1999) Latency of varicella zoster virus; a persistently perplexing state. Front Biosci 4: D200-211.
36. Myers MG, Duer HL, Hausler CK, (1980) Experimental infection of guinea pigs with varicella-zoster virus. J Infect Dis 142: 414-420.
37. Wroblewska Z, Valyi-Nagy T, Otte J, Dillner A, Jackson A, et al. (1993) A mouse model for varicella-zoster virus latency. Microb Pathog 15: 141-151.
38. Myers MG, Connelly BL, Stanberry LR, (1991) Varicella in hairless guinea pigs. J Infect Dis 163: 746-751.
39. Myers MG, Connelly BL, (1992) Animal models of varicella. J Infect Dis 166 (Suppl 1): S48-50.
40. Ku C-C, Besser J, Abendroth A, Grose C, Arvin AM, (2005) Varicella-Zoster Virus Pathogenesis and Immunobiology: New Concepts Emerging from Investigations with the SCIDhu Mouse Model. J Virol 79: 2651-2658.
41. Gray WL, Oakes JE, (1984) Simian varicella virus DNA shares homology with human varicella-zoster virus DNA. Virology 136: 241-246.
42. Gray WL, Pumphrey CY, Ruyechan WT, Fletcher TM, (1992) The simian varicella virus and varicella zoster virus genomes are similar in size and structure. Virology 186: 562-572.
43. Gray WL, Starnes B, White MW, Mahalingam R, (2001) The DNA sequence of the simian varicella virus genome. Virology 284: 123-130.
44. Mahalingam R, Traina-Dorge V, Wellish M, Smith J, Gilden DH, (2002) Naturally acquired simian varicella virus infection in African green monkeys. J Virol 76: 8548-8550.
45. Gray WL, (2003) Pathogenesis of simian varicella virus. J Med Virol 70 (Suppl 1): S4-8.
46. Messaoudi I, Barron A, Wellish M, Engelmann F, Legasse A, et al. (2009) Simian varicella virus infection of rhesus macaques recapitulates essential features of varicella zoster virus infection in humans. PLoS Pathog 5: e1000657.
47. Arvin AM, (1996) Varicella-zoster virus. Clin Microbiol Rev 9: 361-381.
48. Ku CC, Padilla JA, Grose C, Butcher EC, Arvin AM, (2002) Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers. J Virol 76: 11425-11433.
49. Ku C-C, Zerboni L, Ito H, Graham BS, Wallace M, et al. (2004) Varicella-Zoster Virus Transfer to Skin by T Cells and Modulation of Viral Replication by Epidermal Cell Interferon-{alpha}. J Exp Med 200: 917-925.
50. Mehta SK, Cohrs RJ, Forghani B, Zerbe G, Gilden DH, et al. (2004) Stress-induced subclinical reactivation of varicella zoster virus in astronauts. J Med Virol 72: 174-179.
51. Mehta SK, Tyring SK, Gilden DH, Cohrs RJ, Leal MJ, et al. (2008) Varicella-Zoster Virus in the Saliva of Patients with Herpes Zoster. J Infect Dis 197: 654-657.
52. Hayward A, Giller R, Levin M, (1989) Phenotype, cytotoxic, and helper functions of T cells from varicella zoster virus stimulated cultures of human lymphocytes. Viral Immunol 2: 175-184.
53. Gershon AA, Steinberg S, Brunell PA, (1974) Zoster immune globulin. A further assessment. N Engl J Med 290: 243-245.
54. Soike KF, (1992) Simian varicella virus infection in African and Asian monkeys. The potential for development of antivirals for animal diseases. Ann N Y Acad Sci 653: 323-333.
55. Soike KF, Rangan SR, Gerone PJ, (1984) Viral disease models in primates. Adv Vet Sci Comp Med 28: 151-199.
56. Weller TH, (1983) Varicella and Herpes Zoster. N Engl J Med 309: 1362-1368.
57. Vossen MT, Biezeveld MH, de Jong MD, Gent MR, Baars PA, et al. (2005) Absence of circulating natural killer and primed CD8+ cells in life-threatening varicella. J Infect Dis 191: 198-206.
58. Nakanishi Y, Lu B, Gerard C, Iwasaki A, (2009) CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 462: 510-513.
59. Diaz PS, Smith S, Hunter E, Arvin AM, (1989) T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol 142: 636-641.
60. Hickling JK, Borysiewicz LK, Sissons JG, (1987) Varicella-zoster virus-specific cytotoxic T lymphocytes (Tc): detection and frequency analysis of HLA class I-restricted Tc in human peripheral blood. J Virol 61: 3463-3469.
61. Hayward AR, Pontesilli O, Herberger M, Laszlo M, Levin M, (1986) Specific lysis of varicella zoster virus-infected B lymphoblasts by human T cells. J Virol 58: 179-184.
62. Milikan JCM, Baarsma GS, Kuijpers RWAM, Osterhaus ADME, Verjans GMGM, (2009) Human Ocular-Derived Virus-Specific CD4+ T Cells Control Varicella Zoster Virus Replication in Human Retinal Pigment Epithelial Cells. Invest Ophthalmol Vis Sci 50: 743-751.
63. Milikan JCM, Kuijpers RWAM, Baarsma GS, Osterhaus ADME, Verjans GMGM, (2006) Characterization of the varicella zoster virus (VZV)-specific intra-ocular T-cell response in patients with VZV-induced uveitis. Exp Eye Res 83: 69-75.
64. Vossen MT, Gent MR, Weel JF, de Jong MD, van Lier RA, et al. (2004) Development of virus-specific CD4+ T cells on reexposure to Varicella-Zoster virus. J Infect Dis 190: 72-82.
65. Sund F, Lidehall AK, Claesson K, Foss A, Totterman TH, et al. (2010) CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study. Clin Transplant 24: 401-409.
66. Soike KF, Felsenfeld AD, Gerone PJ, (1981) Acyclovir treatment of experimental simian varicella infection of monkeys. Antimicrob Agents Chemother 20: 291-297.